secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001140361-23-052715
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics presents Hydronidone preclinical data at AASLD; plans US clinical program in 2024
--------------------------------------------------------------------------------

- Poster at AASLD Liver Meeting (Nov 10-14, 2023) shows Hydronidone reduces liver fibrosis in mouse models.
- Hydronidone inhibits hepatic stellate cell activation via Smad7-mediated TGF-β degradation.
- Company expects to initiate U.S. clinical program for MASH-associated fibrosis in 2024.
- Specific Smad7 knockdown in vivo blocked Hydronidone's antifibrotic effect, confirming mechanism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123052715/0001140361-23-052715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123052715/ny20009756x16_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-052715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer